BioCentury
ARTICLE | Clinical News

Evolus’ prabotulinumtoxinA meets in head-to-head Phase III for glabellar lines

April 20, 2018 6:47 PM UTC

Evolus Inc. (NASDAQ:EOLS) reported data from the Phase III EVB-003 trial in 540 patients with moderate to severe glabellar lines (frown lines between the eyebrows) showing that a single dose of 20 U prabotulinumtoxinA (DWP-450) met the primary endpoint of non-inferiority to Botox onabotulinumtoxinA in reducing glabellar lines as measured by Glabellar Line Scale (GLS) response rates at day 30 (87.2% vs. 82.8%, 95% CI: -1.9, 10.8). To meet the endpoint, the trial criteria required a lower bound of the 95% CI for the treatment difference to be greater than -10%. The response rate in the placebo arm was 4.2%.

A response in the double-blind, international trial was defined as achieving a GLS score of 0 or 1 point at maximum frown as assessed by the investigator at day 30. Data were reported at the Aesthetic and Anti-Aging Medicine World Congress in Monte Carlo...

BCIQ Company Profiles

Evolus Inc.